Asanmeda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 7,647,868 | 8,064,625 | 9,928,074 | 6,367,960 | 5,687,234 | 6,894,093 | 6,745,463 | 5,729,872 |
| Profit before tax | 77,208 | 106,683 | 1,118,684 | 57,708 | 92,075 | 39,630 | 26,854 | 26,995 |
| Net profit | 61,014 | 89,300 | 944,861 | 50,165 | 77,520 | 28,522 | 18,526 | 21,798 |
| Equity | 6,659,541 | 6,495,751 | 7,440,612 | 7,463,683 | 7,260,156 | 7,241,318 | 7,240,520 | 6,747,096 |
| Liabilities | 1,744,745 | 1,327,397 | 1,316,154 | 840,240 | 739,313 | 1,425,361 | 819,125 | 1,136,214 |
| Non-current assets | 2,417,722 | 2,320,626 | 2,214,126 | 2,309,720 | 2,269,153 | 2,238,881 | 2,405,122 | 2,358,954 |
| Current assets | 5,986,564 | 5,502,522 | 6,542,640 | 5,994,203 | 5,730,316 | 6,427,798 | 5,654,523 | 5,524,356 |
| Total assets | 8,404,286 | 7,823,148 | 8,756,766 | 8,303,923 | 7,999,469 | 8,666,679 | 8,059,645 | 7,883,310 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 1,097,172 | 1,305,818 | 1,155,686 |
| Social insurance contributions | - | - | - | - | - | 411,861 | 412,222 | 435,051 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -1.9% | +5.4% | +23.1% | -35.9% | -10.7% | +21.2% | -2.2% | -15.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.7% | 1.1% | 10.8% | 0.6% | 1.0% | 0.3% | 0.2% | 0.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.9% | 1.4% | 12.7% | 0.7% | 1.1% | 0.4% | 0.3% | 0.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.8% | 1.1% | 9.5% | 0.8% | 1.4% | 0.4% | 0.3% | 0.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 1.0% | 1.3% | 11.3% | 0.9% | 1.6% | 0.6% | 0.4% | 0.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 54,889 | 62,155 | 81,937 | 59,237 | 62,043 | 82,318 | 87,889 | 80,045 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Asanmeda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-12 | 2026-05-13 | 0.01 |
Asanmeda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-11-02 | 2025-11-06 | 1.4 |
| 2025-10-30 | 2025-11-01 | 1341.46 |
| 2025-03-02 | 2025-03-06 | 15.68 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Asanmeda, UAB (company code 221906050) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, revenue amounted to €5.73M, down 15.1% year on year and 16.9% compared with 2023. Net profit was €21.8K, slightly above the €18.5K earned in 2024 and below the €28.5K recorded in 2023, indicating a broadly stable but very narrow profit base. The profit margin remained low at 0.4% in 2025. The balance sheet was still strong, with total assets of €7.88M, equity of €6.75M and liabilities of €1.14M; equity accounted for 85.6% of assets. Leverage was modest, with debt-to-equity of 0.17, and asset turnover stood at 0.73x. Return on equity and return on assets were both 0.3%, reflecting the limited absolute earnings relative to the capital base. Revenue per employee reached €80.7K, while profit per employee was €307. Overall, the 2023-2025 trend shows declining revenue, positive but restrained profitability, and a conservatively funded asset structure.